instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
What’s the median PFS associated with Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What’s the median PFS associated with Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you provide the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you provide the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
I’d like to know the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd). | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: I’d like to know the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd).
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Do you have information on the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Do you have information on the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median progression-free survival (PFS) for Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median progression-free survival (PFS) for Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you inform me about the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
I’m interested in the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd). | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: I’m interested in the median PFS of Daratumumab+Lenalidomide+Dexamethasone (DRd).
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you tell me the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you tell me the median PFS for Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median PFS rate for Daratumumab+Lenalidomide+Dexamethasone (DRd)? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for Daratumumab+Lenalidomide+Dexamethasone (DRd)?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median PFS rate in patients who have undergone Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median PFS rate in patients who have undergone Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What’s the median PFS rate for patients receiving Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What’s the median PFS rate for patients receiving Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What is the median PFS rate for patients that have undergone Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What is the median PFS rate for patients that have undergone Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
What’s the median rate of PFS in patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: What’s the median rate of PFS in patients treated with Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen? | Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Lenalidomide+Dexamethasone (DRd) regimen?
### Response: Patients treated with the Daratumumab+Lenalidomide+Dexamethasone (DRd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of None. |
Can you tell me the median PFS for Lenalidomide And Dexamethasone (Rd)? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: Can you tell me the median PFS for Lenalidomide And Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
What’s the median PFS associated with Lenalidomide And Dexamethasone (Rd)? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: What’s the median PFS associated with Lenalidomide And Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
Could you provide the median PFS of Lenalidomide And Dexamethasone (Rd)? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: Could you provide the median PFS of Lenalidomide And Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
I’d like to know the median PFS of Lenalidomide And Dexamethasone (Rd). | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: I’d like to know the median PFS of Lenalidomide And Dexamethasone (Rd).
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
Do you have information on the median PFS of Lenalidomide And Dexamethasone (Rd)? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: Do you have information on the median PFS of Lenalidomide And Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
What is the median progression-free survival (PFS) for Lenalidomide And Dexamethasone (Rd)? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: What is the median progression-free survival (PFS) for Lenalidomide And Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
Can you inform me about the median PFS for Lenalidomide And Dexamethasone (Rd)? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: Can you inform me about the median PFS for Lenalidomide And Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
I’m interested in the median PFS of Lenalidomide And Dexamethasone (Rd). | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: I’m interested in the median PFS of Lenalidomide And Dexamethasone (Rd).
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
Could you tell me the median PFS for Lenalidomide And Dexamethasone (Rd)? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: Could you tell me the median PFS for Lenalidomide And Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
What is the median PFS rate for Lenalidomide And Dexamethasone (Rd)? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: What is the median PFS rate for Lenalidomide And Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
What is the median PFS rate in patients who have undergone Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: What is the median PFS rate in patients who have undergone Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
What’s the median PFS rate for patients receiving Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: What’s the median PFS rate for patients receiving Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
Could you provide the median Progression-Free Survival rate for patients treated with Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
What is the median rate of Progression-Free Survival in patients who have been treated with Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
Can you inform me about the median PFS rate in patients that were treated with Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
What is the median PFS rate for patients that have undergone Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: What is the median PFS rate for patients that have undergone Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
Could you tell me the median Progression-Free Survival rate for patients who received Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
What’s the median rate of PFS in patients treated with Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: What’s the median rate of PFS in patients treated with Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
Can you share the median Progression-Free Survival rate in patients who have received Lenalidomide And Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Lenalidomide And Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide And Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 34.4 months, with a 95% CI of (29.6, 39.2). |
Can you tell me the median PFS for Selinexor+Dexamethasone (Sd)? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: Can you tell me the median PFS for Selinexor+Dexamethasone (Sd)?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
What’s the median PFS associated with Selinexor+Dexamethasone (Sd)? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: What’s the median PFS associated with Selinexor+Dexamethasone (Sd)?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
Could you provide the median PFS of Selinexor+Dexamethasone (Sd)? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: Could you provide the median PFS of Selinexor+Dexamethasone (Sd)?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
I’d like to know the median PFS of Selinexor+Dexamethasone (Sd). | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: I’d like to know the median PFS of Selinexor+Dexamethasone (Sd).
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
Do you have information on the median PFS of Selinexor+Dexamethasone (Sd)? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: Do you have information on the median PFS of Selinexor+Dexamethasone (Sd)?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
What is the median progression-free survival (PFS) for Selinexor+Dexamethasone (Sd)? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: What is the median progression-free survival (PFS) for Selinexor+Dexamethasone (Sd)?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
Can you inform me about the median PFS for Selinexor+Dexamethasone (Sd)? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: Can you inform me about the median PFS for Selinexor+Dexamethasone (Sd)?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
I’m interested in the median PFS of Selinexor+Dexamethasone (Sd). | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: I’m interested in the median PFS of Selinexor+Dexamethasone (Sd).
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
Could you tell me the median PFS for Selinexor+Dexamethasone (Sd)? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: Could you tell me the median PFS for Selinexor+Dexamethasone (Sd)?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
What is the median PFS rate for Selinexor+Dexamethasone (Sd)? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: What is the median PFS rate for Selinexor+Dexamethasone (Sd)?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
What is the median PFS rate in patients who have undergone Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: What is the median PFS rate in patients who have undergone Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
What’s the median PFS rate for patients receiving Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: What’s the median PFS rate for patients receiving Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
Could you provide the median Progression-Free Survival rate for patients treated with Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
What is the median rate of Progression-Free Survival in patients who have been treated with Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
Can you inform me about the median PFS rate in patients that were treated with Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
What is the median PFS rate for patients that have undergone Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: What is the median PFS rate for patients that have undergone Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
Could you tell me the median Progression-Free Survival rate for patients who received Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
What’s the median rate of PFS in patients treated with Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: What’s the median rate of PFS in patients treated with Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
Can you share the median Progression-Free Survival rate in patients who have received Selinexor+Dexamethasone (Sd) regimen? | Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Selinexor+Dexamethasone (Sd) regimen?
### Response: Patients treated with the Selinexor+Dexamethasone (Sd) have a median Progression-Free Survival (PFS) rate of 3.7 months, with a 95% CI of (3, 5.3). |
Can you tell me the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: Can you tell me the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
What’s the median PFS associated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: What’s the median PFS associated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
Could you provide the median PFS of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: Could you provide the median PFS of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
I’d like to know the median PFS of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone. | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: I’d like to know the median PFS of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone.
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
Do you have information on the median PFS of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: Do you have information on the median PFS of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
What is the median progression-free survival (PFS) for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: What is the median progression-free survival (PFS) for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
Can you inform me about the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: Can you inform me about the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
I’m interested in the median PFS of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone. | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: I’m interested in the median PFS of Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone.
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
Could you tell me the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: Could you tell me the median PFS for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
What is the median PFS rate for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: What is the median PFS rate for Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
What is the median PFS rate in patients who have undergone Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: What is the median PFS rate in patients who have undergone Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
What’s the median PFS rate for patients receiving Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: What’s the median PFS rate for patients receiving Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
Could you provide the median Progression-Free Survival rate for patients treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
What is the median rate of Progression-Free Survival in patients who have been treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
Can you inform me about the median PFS rate in patients that were treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
What is the median PFS rate for patients that have undergone Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: What is the median PFS rate for patients that have undergone Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
Could you tell me the median Progression-Free Survival rate for patients who received Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
What’s the median rate of PFS in patients treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: What’s the median rate of PFS in patients treated with Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
Can you share the median Progression-Free Survival rate in patients who have received Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen? | Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Once-Weekly Carfilzomib 20/70 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 11.2 months, with a 95% CI of (8.6, 13.0). |
Can you tell me the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: Can you tell me the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
What’s the median PFS associated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: What’s the median PFS associated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Could you provide the median PFS of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: Could you provide the median PFS of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
I’d like to know the median PFS of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone. | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: I’d like to know the median PFS of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone.
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Do you have information on the median PFS of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: Do you have information on the median PFS of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
What is the median progression-free survival (PFS) for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: What is the median progression-free survival (PFS) for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Can you inform me about the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: Can you inform me about the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
I’m interested in the median PFS of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone. | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: I’m interested in the median PFS of Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone.
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Could you tell me the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: Could you tell me the median PFS for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
What is the median PFS rate for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: What is the median PFS rate for Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
What is the median PFS rate in patients who have undergone Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: What is the median PFS rate in patients who have undergone Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
What’s the median PFS rate for patients receiving Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: What’s the median PFS rate for patients receiving Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Could you provide the median Progression-Free Survival rate for patients treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
What is the median rate of Progression-Free Survival in patients who have been treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Can you inform me about the median PFS rate in patients that were treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.